Voyager Therapeutics Inc. (NASDAQ:VYGR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The brokerage currently has a $15.00 price objective on the stock. Zacks Investment Research’s target price would suggest a potential upside of 7.37% from the company’s previous close.

According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other research analysts have also issued reports about the company. Cowen and Company reissued a “buy” rating on shares of Voyager Therapeutics in a research report on Thursday, November 10th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 10th. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $37.00 price target on shares of Voyager Therapeutics in a research report on Sunday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $27.20.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) opened at 13.97 on Tuesday. Voyager Therapeutics has a 1-year low of $8.12 and a 1-year high of $30.54. The company’s market cap is $373.28 million. The stock has a 50 day moving average price of $12.14 and a 200 day moving average price of $12.95.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Voyager Therapeutics by 1,487.3% in the second quarter. Vanguard Group Inc. now owns 312,593 shares of the company’s stock valued at $3,436,000 after buying an additional 292,900 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Voyager Therapeutics by 171.3% in the second quarter. JPMorgan Chase & Co. now owns 288,425 shares of the company’s stock valued at $3,170,000 after buying an additional 182,125 shares during the last quarter. BlackRock Fund Advisors increased its stake in Voyager Therapeutics by 106.8% in the second quarter. BlackRock Fund Advisors now owns 302,971 shares of the company’s stock valued at $3,330,000 after buying an additional 156,443 shares during the last quarter. Partner Investment Management L.P. increased its stake in Voyager Therapeutics by 519.7% in the third quarter. Partner Investment Management L.P. now owns 162,278 shares of the company’s stock valued at $1,948,000 after buying an additional 136,091 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Voyager Therapeutics during the first quarter valued at $873,000. 39.58% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.

5 Day Chart for NASDAQ:VYGR

Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.